Cipla Latest News

  1. Anmarate is engaged in manufacturing and distribution of pharmaceutical products
    Date:13-04-2017
  2. Anmarate is engaged in manufacturing and distribution of pharmaceutical products
    Date:13-04-2017
  3. The agreement is to further develop and commercialize MRX-4TZT, a Tizanidine patch for the management of Spasticity
    Date:07-04-2017
  4. The agreement is to further develop and commercialize MRX-4TZT, a Tizanidine patch for the management of Spasticity
    Date:06-04-2017
  5. Epzicom Tablets had US sales of approximately $346.3 million for the 12 month period ending February 2017
    Date:05-04-2017
  6. Epzicom Tablets had US sales of approximately $346.3 million for the 12 month period ending February 2017
    Date:05-04-2017
  7. Cipla has informed about Press Release titled ‘Cipla Receives Final Approval for Generic Epzicom Tablets’.

    The above information is a part of company’s filings submitted to BSE....

    Date:04-04-2017
  8. The transaction is expected to complete before April 14, 2017
    Date:03-04-2017
  9. The Exchange has sought clarification from Cipla with respect to news article appearing on ET NOW on March 23, 2017 titled ‘USFDA issued import alert on Ciplas Tadalafil drug made at Bhagwanpur unit.’

    Date:23-03-2017
  10. The total consideration of transaction would be ZAR 375 million with potential revision linked to FY2017 performance along with customary adjustment
    Date:06-03-2017
Return to Top
Connect with us Facebook
Connect with us Facebook
Connect with us Linkedin
Connect with us Pintrest
Connect with us Google Plus
Connect with us You Tube
Connect with us Mobile App
Request a Call Back
We will guide you on how to find
the Right stocks at the Right prices.
Mobile
Invalid Mobile Number
x
Thank you for
contacting us.
We will call you
shortly.